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Abstract
Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to 
progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based 
guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based 
recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes 
based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the 
United States Preventive Services Task Force guidelines methodology was selected as reference.
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Introduction
Breast cancer (BC) represents the first cause of invasive can-
cer in the Spanish women, accounting for 29% of all female 
cancers. According to recent data, 26,730 new cases and 
6477 deaths are estimated annually in Spain [1].
Metastatic BC (MBC) remains virtually an incurable dis-
ease, with reported median overall survival (OS) of approxi-
mately 2 years. However, improved OS (up to 5 years) has 
been observed recently for certain subtypes, particularly in 
HER2-positive disease. De novo metastatic disease has bet-
ter 5-year OS that recurrent MBC and prognosis appear to 
improve over time [2].
Patients with loco-regional recurrence (LRBC) may or 
may not be amenable to radical local treatment. Overall, 
according to a Spanish study, an increase in OS has been 
observed in the recent years in LRBC patients [3].
Methodology
The SEOM guidelines have been developed with the con-
sensus of ten breast cancer oncologists from the cooperative 
groups GEICAM (Spanish Breast Cancer Research Group) 
and SOLTI (Spanish Collaborative Group for the Study, 
treatment and other experimental strategies in solid tumors). 
To assign a level of certainty (LC) and a grade of recom-
mendation (GR) to the different statements described in the 
clinical guidelines, the United States Preventive Services 
Task Force (USPSTF) guidelines methodology was selected 
as reference, as the previously adopted for the former version 
of SEOM recommendations [4] (Table 1).
General overview of advanced breast cancer
Goals of treatment
The two main goals for the treatment of MBC patients are 
to improve survival and to optimize the quality of life [5]. 
For LRBC patients for whom a radical approach is not fea-
sible, the aims of the treatment are similar to that in MBC 
patients. Conversely, for those LRBC amenable to a local 
treatment the objectives will be to eradicate all macroscopic 
diseases and to improve both disease-free survival and over-
all survival.
• Since the diagnosis of advanced or recurrent BC is made, 
patients should also be offered appropriate multidisci-
Table 1  Strength of recommendation and level of certainty according to the United States Preventive Services Task Force (USPSTF) after July 
2012 [4]
Category Definition
Strength of recommendations (grade)
 A The USPSTF recommends the service. There is high certainty that the net benefit is substantial
 B The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that 
the net benefit is moderate to substantial
 C The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and 
patient preferences. There is at least moderate certainty that the net benefit is small
 D The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the 
harms outweigh the benefits
 I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evi-
dence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined
Levels of certainty regarding net benefit
 High The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary 
care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore 
unlikely to be strongly affected by the results of future studies
 Moderate The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the 
estimate is constrained by such factors as the number, size, or quality of individual studies; inconsistency of findings across 
individual studies; limited generalizability of findings to routine primary care practice; lack of coherence in the chain of evi-
dence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change 
may be large enough to alter the conclusion
 Low The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: the limited number 
or size of studies; important flaws in study design or methods.; inconsistency of findings across individual studies; gaps in the 
chain of evidence; findings not generalizable to routine primary care practice; lack of information on important health out-
comes. More information may allow estimation of effects on health outcomes
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plinary care, as it may have an impact in OS, including 
symptom-related intervention (LC high; GR A).
• Research is a priority in this setting. Participation in 
well-designed, independent, prospective trials should be 
offered to all eligible patients, whenever possible (LC 
high; GR A).
For all indications and breast cancer types, palliative 
treatment is strongly recommended when indicated.
Diagnosis of recurrence and metastatic disease
• Clinical loco-regional recurrence should be confirmed 
by biopsy in all LRBC before planning any therapeutic 
strategy (LC high; GR A).
• Both in LRBC and in MBC (primary or relapsed) the 
histologic analyses should be performed if possible. In 
recurrences, it will serve to confirm neoplastic recurrence 
and to recheck histologic subtype, as changes in hormone 
receptors (HR) and HER2 between primary tumor and 
recurrences have been reported [6] (LC high; GR A).
Staging
• For both MBC and LRBC clinical evaluation should 
include medical history and physical examination. Mini-
mal staging workup should include imaging techniques 
of chest, abdomen and bone, hematology and biochemis-
try. The recommended imaging techniques are body TC 
and bone scintigraphy (LC moderate; GR B).
• The role of tumor markers (TM) in the follow-up of early 
BC patient is controversial [7] (LC low; GR C). Once 
recurrence is diagnosed, basal TM (CEA, CA15.3 and/
or Ca 27.4) may be performed. Because, if elevated, may 
help to monitor disease response to therapy, especially in 
the presence of non-measurable disease (LC low; GR C). 
However, treatment decisions should not be based only 
on the variation of TM levels (LC moderate; GR A).
• Overall, the use of systematic brain image in all patients 
in the absence of suspicious symptoms is not recom-
mended, even in HER2-positive disease (LC moderate; 
GR B).
• The use of Positron emission tomography (PET) is con-
troversial in MBC, but can be used instead of TC and 
bone scan, if available (level of evidence low, GR B) [8]. 
In the postoperative surveillance   PET/TC is recom-
mended only in cases of equivocal and conflicting find-




Patients with local and regional disease are divided into 
three groups.
• Initial treatment with lumpectomy + radiation therapy 
(RT): treat recurrence with total mastectomy + axillary 
lymph node staging if level II/III axillary dissection not 
previously done [10] (LC moderate; GR B). Limited 
data suggest that a repeated sentinel node biopsy may 
be successfully performed in patients who have previ-
ously undergone breast-conserving therapy and sentinel 
node biopsy [11] (LC low; GR C). For isolated ipsilateral 
breast cancer recurrences, breast conservative surgery 
plus partial breast irradiation is an alternative option [12] 
(LC moderate; GR B).
• Initial treatment with mastectomy and no prior RT: treat 
recurrence with surgical resection if possible + RT [13, 
14] (LC low; GR B).
• Initial treatment with mastectomy + level I/II axillary 
dissection and prior RT: surgical resection if possible 
[13] (LC low; GR B). Limited data regarding additional 
irradiation [15] (LC low; GR C).
Regional only or local and regional recurrence
• Axillary recurrence: surgical resection if possible + RT 
if possible [16] (LC moderate; GR B).
• Supraclavicular and internal mammary node recurrence: 
RT if possible [17] (LC moderate; GR B).
Patients with disease not amenable to radical local treat-
ment should be treated with induction chemotherapy (CT), 
endocrine or anti-HER2 therapy when indicated, and then 
palliative radiation, which is mandatory if the patient is 
radiation naïve [14, 18] (LC low; GR B).
Systemic therapy
CT after first local or regional recurrence improves long-
term outcomes primary in ER negative disease. Endocrine 
therapy in this setting improves long-term outcomes for 
ER positive disease [19] (LC moderate; GR B). In case of 
HER2-positive disease and the absence of previous anti-
HER2 adjuvant treatment, trastuzumab is indicated [20] 
(LC moderate; GR B). However, the optimal strategy in case 
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of previous adjuvant anti-HER2 treatment is unknown. CT 
is indicated for endocrine-resistant disease, as first line in 
triple-negative disease and combined with anti-HER2 drugs 
in HER2-positive disease.
In patients with disease not amenable to radical local 
treatment, the choice of palliative systemic therapy should 
be made according to the principles defined for metastatic 
BC (LC high; GR A).
Endocrine therapy in advanced HR‑positive/
HER2‑negative breast cancer
Since the last SEOM guideline for MBC on 2015 several 
advances have occurred in the treatment of endocrine ther-
apy (ET) of luminal MBC [21]. Endocrine therapy includes 
ER-targeting drugs as single agents or in combination with 
drugs targeting pathways involved in hormone resistance 
such as the mTOR inhibitor, everolimus (PIK3/AKT/mTOR 
pathway) and CDK4/6 inhibitors (cell cycle pathway). ER-
targeting drugs can act by lowering the levels of circulating 
estrogens or those acting directly in the ER (Table 2).
General considerations
The preferred treatment for luminal ABC is ET in the major-
ity of cases. Sequential ET should be used as long as the 
patient seems to be benefiting from ET and does not have 
evidence of immediately life-threatening disease or rapid 
progression of visceral disease with organ dysfunction 
(visceral crisis), or when there is an evidence of endocrine 
resistance. The presence of visceral involvement alone is 
not a contraindication for the use of ET (LC high; GR A).
The choice of which ET to use in each situation should 
take into consideration: (1) prior (neo) adjuvant ET vs “de 
novo” ABC; (2) Disease-free interval; (3) response to prior 
ET; (4) burden of disease and symptoms; (5) menopausal 
status; (6) comorbidities; (7) patient preferences and (8) 
costs and availability.
Since eventually all patients develop resistance or primar-
ily resistant to ET, this must be considered before starting 
any therapy (first or next lines). Although a clear and con-
sistent definition of resistance to ET is lacking, endocrine 
resistance has been defined by consensus (Table 3), as well 
as the type of ET that should be used in first and second lines 
(Table 4) [5, 22].
The optimal sequence of endocrine-based therapy is 
uncertain. Available options for pre- and perimenopausal 
women with ovarian function suppression (OFS)/ovarian 
Table 2  Common classes of 
endocrine therapy
Mechanism of action
SERM selective estrogen receptor modulator, SERD selective estrogen receptor downregulator (Fulvestrant 
500 mg/month with loading dose is the recommended dosage), GnRH gonadotropin-hormone releasing-
hormone, NSAI non-steroideal aromatase inhibitors (3rd generation), SAI steroidal aromatase inhibitors 
(3rd generation)
Mechanism of action Class Agent
Estrogen receptor blockage SERM Tamoxifen, toremifen
SERD Fulvestrant
Estrogen deprivation Ovarian ablation Surgery, radiation








Unknown Progestins Megestrol acetate
Medroxyprogesterone acetate
High-dose estrogens Diethylstilbestrol (DES)
Table 3  Definition of endocrine resistance levels [5, 22]
Primary endocrine resistance Relapse while on the first 2 years of adjuvant endocrine therapy (ET), or progressive disease (PD) within first 
6 months of first-line ET for ABC, while on ET
Secondary endocrine resistance Relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant 
ET, or PD ≥ 6 months after initiating ET for ABC, while on ET
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function ablation (OFA), and post-menopausal women 
include aromatase inhibitor (AI), tamoxifen, fulvestrant, AI/
fulvestrant plus CDK 4/6 inhibitor, and ET plus everolimus. 
In later lines, also megestrol acetate and oestradiol, as well 
as repetition of previously used agents, may be used.
Besides the ER/PR positivity, as defined by international 
guidelines [23], we do not have another useful biomarker 
to select ET.
As the blockage of the estrogen signal is the mainstay of 
the treatment and the estrogen level varies depending on the 
menopausal status, it is important to define the situation of 
each patient (Table 5) [24].
Postmenopausal women
First‑line setting
• Third generation AIs Anastrozole, letrozole (non-
steroidal aromatase inhibitors, NSAI) and exemes-
tane (steroidal aromatase inhibitor, SAI) are supe-
rior to tamoxifen. There are no differences in 
efficacy between the three AIs [25] (LC high; GR A). 
• Fulvestrant 500 mg has better progression free survival 
(PFS) than anastrozol (18 vs 13 months), without dif-
ferences in OS in patients without prior exposure to ET, 
particularly in those with non-visceral disease [26].
• The combination of an NSAI or fulvestrant plus CDK4/6 
inhibitor has consistently shown to increase PFS in about 
10 months compared to ET alone, although with more 
toxicity, and the effect is consistent in all trials and in all 
clinical subgroups.
The three options (AI, fulvestrant 500 mg and AI/ful-
vestrant + CDK4/6 inhibitor) are valid for the first line. 
Tamoxifen is also an option, if others cannot be used. The 
combination of ET plus CDK4/6 inhibitor is the preferred 
one if no other contraindications are present. [5, 22, 25, 26] 
(LC high; GR A).
• For patients that received chemotherapy as first line 
of treatment, maintenance ET is a reasonable option, 
although not assessed in clinical trials [5, 22]. There 
is somewhat less evidence for combination of ET with 
CDK4/6 inhibitors in this situation; so, our recommen-
dation is to consider the use of ET alone, taking into 
account the toxicity and QoL variables (LC low; GR B).
Second‑line setting
The second line will depend on which drug has been used 
as first line.
• AI is better than progestin, and similar to fulvestrant 
250 mg. In second line fulvestrant 500 mg is better than 
250 mg [21].
• For those patients treated with prior AIs, fulvestrant 500 
would be the optimal option. [27]. Also, the alternate 
Table 4  Consensus definition of 1st and 2nd lines of endocrine therapy (ET) [5, 22]
1st line ET: (endocrine sensitive patients) Newly diagnosed (de novo) ABC
Relapse > 12 months from completion of (neo) adjuvant endocrine therapy with no treat-
ment for advanced or metastatic disease (treatment naïve in the advanced setting)
2nd line ET Relapse on or within 12 months from completion of (neo) adjuvant endocrine therapy 
with no treatment for advanced or metastatic disease (early relapse)
Progression after 1st line of endocrine therapy for advanced disease (as described before)
Table 5  Definitions and menopausal status [24]
Menopause Is the permanent cessation of menses




Age < 60 years and amenorrheic for 12 or more months in the absence 
of chemotherapy, tamoxifen, toremifene, or ovarian suppression and 
follicle-stimulating hormone (FSH) and estradiol in the postmeno-
pausal range
If taking tamoxifen or toremifene, and age < 60 years, then FSH and 
plasma estradiol level must be in postmenopausal ranges
It is not possible to assign menopausal status to women who are receiving an LHRH agonist or antagonist
In therapy-induced amenorrhea, oophorectomy or serial measurement of FSH and/or estradiol are needed to ensure postmenopausal status if 
the use of aromatase inhibitors is considered as a component of endocrine therapy
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class of AI can be considered. Switching between ste-
roidal and non-steroidal AIs produces modest additional 
clinical benefits, suggesting partial non-cross-resistance 
between the classes of inhibitor. However in these cir-
cumstances, the response rates to the second AI have 
generally been low [28].
• The combination of CDK4/6 inhibitors + fulvestrant has 
proven to be better than fulvestrant alone in patients with-
out prior exposure to CDK4/6 inhibitors after progres-
sion to AIs, with increase in PFS [29–31] (LC high; GR 
A).
• Also, the combination of the mTOR (mammalian target 
of rapamycin) inhibitor everolimus with ET (exemes-
tane in a phase III trial, and also with tamoxifen and 
fulvestrant in phase II trials) after progression to an AI 
leads to an increased PFS compared with ET alone, but 
with worse tolerance (see review in next section).
There are no data to define the best choice of treatment 
after progression to a CDK4/6 inhibitor in first line.
Subsequent lines of therapy
There is very limited information from prospective trials 
in patients with prior exposition to more than two lines 
of ET. In cases where a positive effect has been achieved 
with prior ET, those ET not previously used and progestins 
and other ET (Table 2) can be tested [5, 22] (LC moder-
ate; GR B).
Premenopausal women
• There are less data for premenopausal women treated 
with endocrine therapy alone, as many trials with ET 
have included mainly postmenopausal women. However, 
the old data with OFS in combination with tamoxifen, 
small trials with OFS and AI or fulvestrant and data of 
premenopausal patients included in new trials of ET with 
CDK4/6 inhibitors have proven that the benefit in pre-
menopausal women is comparable to that obtained in 
postmenopausal [32, 33]. For all these reasons the inter-
national consensus is that the optimal management of 
pre/perimenopausal patients with luminal ABC consists 
of the induction of OFS or OFA in combination with 
another endocrine agent. Once the patient has been ren-
dered postmenopausal, recommendations for postmeno-
pausal apply (LC high; GR A).
• Adequate OFS for ABC premenopausal patients can be 
obtained through bilateral ovariectomy, continuous use of 
 LHRH agonists or OFA through pelvic RT (this latter is 
not always effective, and therefore is the least preferred 
option) [5, 22] (LC high; GR A).
• For those patients that do not desire ovarian suppression, 
tamoxifen is a reasonable option (LC high; GR B).
Endocrine therapy in men
There are few data in these populations. International guide-
lines recommendations are that treatment should be chemi-
cal castration with GnRH analogs and then combination 
with ET as in postmenopausal women. Also, for those that 
do not want castration tamoxifen is a reasonable option [5] 
(LC moderate; GR A).
Chemo‑endocrine therapy
There is no clear evidence that concomitant use of ET plus 
chemotherapy results in improvement in OS. Therefore, 
this combination should be discouraged outside a clinical 
trial [34] (LC low; GR D).
Duration of ET
ET should be continued until progressive disease or tox-
icity. For those patients treated with combined therapy 
(CDK4/6 inhibitors or everolimus) who have severe tox-
icity to the non-hormone component of the combination 
ET alone can be used until progression (LC high; GR A).
Targeted therapy in advanced breast cancer
CDK4/6 inhibitors: palbociclib, ribociclib 
and abemaciclib
The combination of a CDK 4/6 inhibitor with an AI is 
the preferred first-line option for most patients with endo-
crine-sensitive HR-positive/HER2-negative metastatic 
breast cancer (Table 2) [35–37] (LC high; GR A).
Recent evidence suggests the efficacy of the combina-
tion of CDK4/6 inhibitor with fulvestrant in first-line set-
ting and endocrine-sensitive disease [30] (LC high; GR A).
The option of CDK4/6 inhibitor with an AI would also 
be appropriate for those patients who have not received 
prior treatment with a CDK4/6 inhibitor (LC moderate; 
GR B).
For patients with endocrine-resistant HR-positive/
HER2-negative disease (Table 2) ABC, the combination of 
a CDK4/6 inhibitor with fulvestrant is the preferred option. 
[29–31, 38] (LC high; GR A).
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Both combinations (CDK/AI and CDK/fulvestrant) are 
applicable regardless of the patient’s menopausal status, 
although pre/perimenopausal patients additionally will 
require ovarian function ablation or suppression.
Considering all these data, a CDK4/6 inhibitor should be 
added to endocrine therapy, at the latest when starting sec-
ond-line endocrine therapy. Because the side effect profile of 
the CDK4/6 inhibitors appears substantially more tolerable 
than that seen with everolimus, the panel of experts recom-
mends using CDK4/6 inhibitors rather than everolimus as 
the initial-targeted therapy to partner with ET.
With the exception of HR status, at present there are no 
validated predictive biomarkers to identify those women 
who could benefit from endocrine-based therapy with a 
CDK4/6 inhibitor (Table 6).
mTOR inhibitors: everolimus
The combination of an AI with everolimus, an mTOR inhibi-
tor, can be a valid treatment option for patients with endo-
crine-resistant HR-positive/HER2-negative metastatic breast 
cancer, since they are likely to obtain a significantly longer 
median PFS compared to aromatase inhibitor monotherapy 
(7.8 vs 3.2 months) [39, 40].
However, as an OS benefit could not be proved [41], when 
considering this targeted therapy, special attention must be 
paid to the increased toxicity including potentially severe 
side effects (e.g., non-infectious pneumonitis) (LC high; GR 
B). Primary prophylactic measures (e.g. mouthwashes with 
dexamethasone and meticulous oral hygiene) are recom-
mended to prevent troublesome side effects [42]. Elderly 
patients should be closely monitored during treatment with 
proactive management of side effects.
With the exception of HR status, at present there are no vali-
dated predictive markers to identify those women who could 
benefit from endocrine-based therapy with a mTOR inhibitor.
PARP inhibitors: olaparib and talazoparib
The poly-(ADP-ribose)-polymerase (PARP) inhibitors 
olaparib and talazoparib are both useful treatment options 
for patients with advanced germline BRCA1/2-mutated 
triple-negative breast cancer (TNBC) or HER2-negative 
luminal-like breast cancer [43, 44]. Specifically, olaparib 
has been recently approved by EMA to treat metastatic 
breast cancer after progression on chemotherapy. Patients 
should have received previous treatment in the form of (neo) 
adjuvant therapy or up to two lines of chemotherapy with 
anthracyclines and taxanes for metastatic disease, and must 
not have platinum-resistant disease.
This recommendation is based on longer PFS (approxi-
mately 3 months), higher overall response rate, good side 
effect profile and an improved quality of life with both PARP 
inhibitors compared to physician’s choice of standard chem-
otherapy (capecitabine, eribulin, or vinorelbine) in two ran-
domized phase III trials (OlympiAD and EMBRACA trials) 
[43, 44] (LC high; GR A).
Treatment of HER2‑positive advanced breast 
cancer
First‑line therapy
The initial treatment approach to HER2-positive MBC must 
include a combination of chemotherapy and anti-HER2 ther-
apy [45]. The same HER2 targeting agent should continue 
beyond progression through subsequent lines of treatment 
[46] (LC high; GR A).
Dual-blockade with trastuzumab, pertuzumab and taxanes 
is the treatment of choice in the first-line setting following the 
results of phase III CLEOPATRA trial that demonstrates a sta-
tistical significant improvement in PFS and OS from adding 
pertuzumab to trastuzumab and docetaxel [47] (LC high; GR 
A).
Replacing taxane with vinorelbine may be considered in 
certain circumstances [48] (LC low; GR C).
Of note, only 10% of CLEOPATRA patients were previ-
ously exposed to trastuzumab. In the PHEREXA trial testing 
trastuzumab plus capecitabine with or without pertuzumab, a 
smaller benefit from addition of pertuzumab to trastuzumab-
exposed MBC patients in second-line setting was reported [49].
Trastuzumab emtansine (T-DM1) was non-inferior to 
trastuzumab-taxane in the phase III first-line MARIANNE 
study. However, there are no data regarding a head-to-head 
comparison between T-DM1 and dual HER2-blockade with 
Table 6  Comparison of the status of authorization of CDK4/6 inhibi-
tors
HR +/HER2 − ABC hormone receptor-positive and HER2-negative 
Advanced Breast Cancer, AI aromatase inhibitor, ET endocrine therapy
a Endocrine therapy must be combined with a luteinizing hormone–
releasing hormone (LH–RH) agonist in pre or perimenopausal women
EMA Indication
PALBOCICLIB HR +/HER2 − ABC in combination with:
 An  AIa
 Fulvestrant, in women previously treated with 
 ETa
RIBOCICLIB Women with HR +/HER2 − ABC, in combina-
tion with an AI or Fulvestrant as initial ET or in 
women who have received prior  ETa
ABEMACICLIB Women with HR +/HER2 − ABC in combination 
with an AI or Fulvestrant, as initial ET or in 
women previously treated with  ETa
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trastuzumab, pertuzumab and a taxane. Consistently, T-DM1 
is generally reserved for second-line setting [50]. One excep-
tion could be in cases of fast progression on/after adjuvant 
trastuzumab (6–12 months) or if the patient is not suitable 
for taxanes and dual blockade [51, 52] (LC moderate; GR B).
Second‑line therapy
T-DM1 is the recommended regimen for second-line therapy, 
as in the phase III EMILIA trial. It demonstrated superiority 
over lapatinib and capecitabine in terms of PSF and OS [53] 
(LC high; GR A). However, it should be noted that there are 
limited data about T-DM1 efficacy in pertuzumab exposed 
patients.
Pertuzumab, trastuzumab and chemotherapy may be con-
sidered as second line in patients previously not exposed 
to pertuzumab, and lapatinib and capecitabine are suitable 
options if T-DM1 was used as first line or it is contraindicated 
[51, 52] (LC moderate; GR B).
Third‑line therapy and beyond
Regimens currently recommended for first or second line 
should be considered for the later lines, if not used previously 
[5] (LC low; GR C).
T-DM1 demonstrated superiority over treatment of physi-
cian’s choice in third and later lines in phase III TH3RESA 
trial [54] (LC high; GR A).
Despite the proven activity of lapatinib and capecitabine in 
the second line [55], this combination was inferior to T-DM1 
in EMILIA trial, so it preferably should be used afterwards 
(LC moderate; GR B).
Trastuzumab plus different chemotherapies (vinorelbine, 
capecitabine, gemcitabine) may be an option if not used previ-
ously (LC low; GR C).
Trastuzumab and lapatinib are also an option [56] (LC mod-
erate; GR B).
The number and duration of each treatment line with 
HER2-targeted therapy and chemotherapy combinations 
cannot be established. The chemotherapy should continue 
for approximately 6 months (or longer) and/or to the time of 
maximal response, depending on toxicity and in the absence of 
progression. When chemotherapy is stopped, clinicians should 
continue the HER2-targeted therapy. Available data suggest 
that the benefit is maintained in third line and further therapy 
[51, 52] (LC moderate; GR B).
HR‑positive HER2‑positive MBC
The first treatment approach in this population is HER2-tar-
geted therapy plus chemotherapy (LC high; GR A).
In selected cases (including those with contraindications 
to chemotherapy, patient’s with a strong preference against 
chemotherapy or those with a long disease-free interval, mini-
mal disease burden, in particular in terms of visceral involve-
ment, and/or strong ER/PR expression) ET plus trastuzumab 
or lapatinib can be an option [57, 58] (LC moderate; GR B).
If a regimen of HER2-targeting therapy and chemotherapy 
is started, ET may be added to the HER2-targeted therapy 
when chemotherapy ends [51, 52] (LC low; GR C).
Treatment of triple‑negative advanced 
breast cancer
TNBC is characterized by the absence of expression of 
ER, PR, and HER2. TNBC is a heterogeneous entity. 
There is a significant overlap of TNBC with basal-like 
subtype by PAM50, although they are no synonyms [59].
Chemotherapy (CT) is the standard treatment for 
patients with TNBC [60]. The choice of the strategy and 
cytotoxic agents is conditioned by a large number of 
factors and must be considered individually. In general, 
sequencing single agent chemotherapy is preferred [61], 
limiting combination therapies for patients with aggres-
sive, symptomatic or life-threatening disease [51] (LC 
high; GR A).
The optimal duration of CT is not well established, but 
generally a given regimen should be used until progres-
sion of disease or unacceptable toxicity [62] (as defined 
together with the patient) (LC moderate; GR B).
Given the aggressiveness of the disease and the limited 
effective treatment options, patients with metastatic TNBC 
should always be offered participation in well designed, 
prospective, independent trials whenever such trials are 
available, and the patient is willing to participate (LC 
high; GR A).
First‑line treatment
• In patients that are CT-naïve, anthracyclines or taxanes, 
either alone or in combinations are considered as first-
line treatment [63] (LC high; GR A). This recommen-
dation is also valid for patients with late recurrences 
(> 1 year) after completing (neo) adjuvant anthracy-
clines and/or taxanes.
• In patients with taxane-naïve and anthracycline-resist-
ant MBC, or with anthracycline cumulative dose or tox-
icity who are being considered for further CT, taxane-
based therapy, preferably as single agent would usually 
be considered as the therapy of choice (LC high; GR 
A). In patients pretreated with adjuvant taxanes and 
anthracyclines, other options such as vinorelbine [64, 
65] and capecitabine [66] are also available (LC moder-
ate; GR B).
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• Bevacizumab, a humanized anti-VEGF monoclo-
nal antibody, improves PFS and overall response 
rate (ORR), but not OS, when combined with taxa-
nes or capecitabine in HER2-negative MBC patients 
[67–70] and may be considered for selected patients 
with aggressive or symptomatic disease (LC moder-
ate; GR C). In the absence of predictive biomarkers, 
this benefit must be weighed against its toxicity profile 
(hypertension, proteinuria, and hemorrhagic events) 
[71]. Maintenance therapy with bevacizumab plus 
capecitabine (compared to bevacizumab alone) after 
induction first-line treatment with bevacizumab plus 
docetaxel improves PFS and OS for HER2-negative 
MBC patients (PFS 11.9 vs 4.3 months) [72]. Given 
these results, capecitabine plus bevacizumab may be 
considered for selected cases after initial CT with doc-
etaxel plus bevacizumab (LC low; GR C).
• The combination of carboplatin and gemcitabine has 
been accepted as control arm by EMA and FDA in ran-
domized trials, and actually showed a significant activ-
ity (PFS of around 5 months and median OS of around 
1 year as first-line therapy) [73]. The combination is 
active in patients resistant to anthracyclines and taxa-
nes, and it is an acceptable option in young patients with 
aggressive symptomatic disease (LC moderate; GR B).
• Carboplatin as first-line treatment for patients with 
TNBC and/or germline BRCA1- or BRCA2-associated 
MBC (gBRCA) was as effective as docetaxel in the rand-
omized phase III TNT trial [74]. Although there were no 
differences in ORR or PFS in the unselected population 
(ORR, carboplatin 31.4% vs docetaxel 34.0%), gBRCA 
mutation carriers had an absolute difference of 34.7% in 
ORR (68% vs 33%, p = 0.03; biomarker, treatment inter-
action p = 0.01), which also translated in significant dif-
ferences in PFS (6.8 vs. 3.1 months, p = 0.04). Based on 
these results, carboplatin can be considered as an option 
both for unselected TNBC patients (LC moderate; GR B) 
and for gBRCA MBC (LC high; GR A).
• Atezolizumab in combination with nab-paclitaxel 
has shown to improve PFS in patients with metastatic 
TNBC when compared to nab-paclitaxel alone [75]. 
This was achieved both in the intent-to-treat population 
(7.2 vs 5.5 months; HR 0.80) and among patients with 
PD-L1-expressing tumors in the infiltrating immune 
cells. In the intention-to-treat analysis, the median OS 
was 21.3 months with atezolizumab plus nab-paclitaxel 
and 17.6 months with placebo plus nab-paclitaxel (HR 
0.84; p = 0.08), and among patients with PD-L1-pos-
itive tumors, the median OS was 25.0  months and 
15.5 months, respectively. Although encouraging, addi-
tional results of trials testing immunotherapy agents plus 
chemotherapy must be awaited before a recommendation 
can be made to incorporate immunotherapy in first-line 
treatment for TNBC.
Second and further lines of treatment
There is no limit to the number of therapy lines to be pro-
posed to metastatic TNBC patients, as long as a good quality 
of life is maintained [51].
In patients pretreated with an anthracycline and a tax-
ane, and who do not need combination CT, single-agent 
capecitabine, vinorelbine (oral or IV), and eribulin are the 
preferred choices [64, 65, 76, 77] (LC moderate; GR B). 
Additional choices include an alternative taxane (standard 
or nab-paclitaxel), rechallenge with anthracyclines (liposo-
mal formulation), gemcitabine, or platinum agents [78] (LC 
moderate; GR B).
Chemotherapy in luminal‑advanced breast 
cancer
Chemotherapy should be the standard treatment for HR-pos-
itive MBC patients that are refractory to endocrine therapy, 
and for those women with triple-negative MBC [5] (see rec-
ommendations in the TNBC section).
Anthracyclines, taxanes, vinorelbine, capecitabine, gem-
citabine and eribulin are reasonable and available options. 
The choice of the strategy and cytotoxic agents must be con-
sidered individually, taking into account previous therapies 
and their toxicities, tumor burden, time until recurrence after 
prior therapy, biological age, performance status, comor-
bidities, estimate life expectancy, need for a rapid disease/
symptom control and patient’s preferences [5, 79]. No par-
ticular chemotherapeutic agent or regimen has been able to 
provide consistent gains in survival in these patients [79]. In 
general, sequencing single-agent chemotherapy is preferred 
[61, 80], limiting combination therapies for patients with 
aggressive, symptomatic or life-threatening disease (at least 
same efficacy, less toxicity) [5] (LC high; GR A).
Evaluation of response to chemotherapy should generally 
occur after two to four cycles depending on the dynamics 
of the disease, the location and extent of metastatic involve-
ment and type of treatment. Imaging of target lesions may be 
sufficient in many patients (LC moderate; GR B) [5]. Subjec-
tive and objective toxicities must be evaluated repeatedly, as 
well as the symptoms and performance status. Duration of 
each regimen and the number of regimens should be tailored 
to each individual patient.
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First‑line treatment
• In the absence of medical contraindications or patient 
concerns, anthracyclines or taxanes, either alone (pref-
erably) or in form of combinations, are considered 
the first-line chemotherapy of choice, particularly in 
patients without prior adjuvant chemotherapy or with 
late relapses (LC high; GR A). After pretreatment with 
anthracyclines, the first options are taxanes, preferably 
using weekly paclitaxel or docetaxel every 3 weeks (LC 
high; GR A). Nanoparticle albumin-bound (nab)-pacli-
taxel as weekly or 3-weekly schedule is an alternative 
option (LC moderate; GR B).
• The combination of bevacizumab plus taxanes improves 
PFS and ORR, but not OS versus chemotherapy alone 
and should also be considered a first-line chemotherapy 
option in selected cases [69, 70, 81] (LC moderate; GR 
B) (see recommendations in the TNBC section).
• In patients pretreated with adjuvant taxanes and anthra-
cyclines, other options such as vinorelbine [64, 65] and 
capecitabine [66] are also appropriate first-line chemo-
therapy options (LC moderate; GR B) (see recommenda-
tions in the TNBC section).
Second and further lines of chemotherapy
• A large number of agents have shown activity as sec-
ond-line chemotherapy and beyond in HR-positive MBC 
and may be suitable for sequential treatment in selected 
patients. Among them, capecitabine, vinorelbine, gemcit-
abine, nab-paclitaxel, liposomal doxorubicin and eribulin 
are approved options and can be appropriate therapies 
[65, 76, 77, 82, 83].
• In a phase III trial in patients pretreated with taxanes and 
anthracyclines, eribulin was not superior to the current 
standard capecitabine in PFS or OS. In another phase 
III trial, eribulin has shown a modest improvement in 
OS in patients with prior taxanes, anthracyclines and 
capecitabine. Therefore, it is the CT drug of choice in 
this population (LC high; GR A).
Considering these data, capecitabine is the most recom-
mendable first option for HR-positive MBC patients pre-
treated with taxanes and anthracyclines, while eribulin can 
be administered after progression on capecitabine (LC high; 
GR A).
Drug rechallenge may be appropriate in selected 
cases; taxane rechallenge should not be performed within 
12 months after the last taxane treatment [84] (LC moderate; 
GR B). Liposomal doxorubicin might be used in the same 
indications [85] (LC low; GR C).
Special situations: CNS, bone, primary tumor
Treatment of central nervous system metastases
Brain metastases is a frequent and challenging situation that 
affects up to 10–30% of all breast cancer patients during 
the course of their disease [86], being the HER2-positive 
and TNBC groups those with the highest incidence (up to 
40%). Brain metastases are associated with the shortest 
survival time compared with other sites of metastatic dis-
ease in breast cancer [87], although a sizeable fraction of 
these patients may reach a prolonged survival (2 years and 
beyond), due to the higher efficacy of the novel local and 
systemic therapies.
A modified breast-graded prognostic assessment (GPA) 
index has recently been postulated [88, 89]. It integrates four 
simple clinical characteristics (age, Karnofsky score, num-
ber of brain metastases (BM) and breast cancer subtype) and 
may serve to guide further treatments in BM breast cancer 
patients.
Local therapies
Surgery Might be considered in specific circumstances: high 
breast-GPA index, 1–3 brain metastases, systemic disease 
under control, when BM are symptomatic and not respond-
ing to other therapies, and finally for diagnostic purposes 
[90] (LC moderate; GR B).
Stereotactic radiotherapy Stereotactic uses high con-
formal radiation that applies high doses of RT (15–25 Gy) 
in one or a few sessions [91]. This treatment is generally 
indicated in selected cases of oligometastatic disease (≤ 3 
metastases) and can be considered an alternative to surgery 
[92] (LC moderate; GR B).
Whole brain radiation therapy (WBRT) Consists in the 
administration of 30 Gy in 10 fractions to the brain. This 
strategy, although palliative and indicated for symptomatic 
relief, has also an impact on BM breast cancer evolution as it 
has demonstrated a prolongation in OS versus best support-
ive care [93]. WBRT is generally recommended when there 
are multiple lesions (≥ 3 metastases), and/or when lesions 
are higher than 3 cm or have a volume of ≥ 25 cm3 [94] (LC 
moderate; GR B).
Systemic treatments
The value of systemic treatments on local control of brain 
metastases is unclear. A personalized approach attending BC 
subtype, disposable therapies and Karnofsky score is highly 
advisable (LC moderate; GR B).
41Clinical and Translational Oncology (2019) 21:31–45 
1 3
Chemotherapy Although there are currently no specifi-
cally systemic treatments approved for BMBC, agents like 
capecitabine and topotecan, have demonstrated activity 
in this setting as with BM overall responses in the range 
of 38–60% [95–98]. In the case of combinations, cispl-
atin and etoposide, cisplatin and temozolomide, CMF and 
CAF schedules reach a response rate quite similar to those 
obtained in extracranial disease, ranging from 38 to 76% 
[95].
Targeted therapies and endocrine-therapy Nowadays, 
targeted therapies for BMBC remain confined to HER2 
advanced BC disease, although evidence is not clear. 
Improved survival with trastuzumab in HER2-positive BM 
breast cancer has been attributed to a better control of extrac-
ranial systemic disease [99].
Lapatinib alone does not seem particularly active in BM 
breast cancer, although results seem to improve when com-
bined with capecitabine [100].
With respect to T-DM1 a subset analysis of the EMILIA 
trial showed that among patients with treated and stable 
brain metastases at baseline (n = 95), a significant improve-
ment in OS was observed in the T-DM1 arm with a hazard 
ratio of 0.38 (p = 0.008), median OS 26.8 vs 12.9 months 
[101]. More data from prospective trials are needed to ascer-
tain the real efficacy of T-DM1 in BM breast cancer.
The anti-VEGF monoclonal antibody bevacizumab seems 
to improve results when combined with carboplatin [102, 
103], but more solid evidences are needed.
Solid evidence for efficacy of endocrine therapy, PARP 
inhibitors, CDK4/6 inhibitors, in BM breast cancer is 
lacking.
Role of local therapies in MBC
They are indicated for symptoms palliation and prevention 
of cancer-related complications (LC moderate; GR B). Evi-
dence regarding survival prolongation is contradictory and 
elusive.
• Local therapy of the primary tumor in the novo MBC 
Routine breast surgery cannot be recommended in de 
novometastatic BC in patients who are asymptomatic at 
the site of their primary (LC moderate; GR B), provided 
that conflicting results from meta-analysis [104–106] and 
two prospective trials are obtained [107, 108].
The role of surgery for extracranial metastasis in MBC
• Can be considered after a balanced decision process and 
on a case-by-case basis (LC low; GR C).
• Oligometastatic disease in fit patients with long-term 
disease-free intervals or good response to previous sys-
temic treatments could be considered as criteria for sur-
gery with a curative intent (LC low; GR C).
The role of radiotherapy for extracranial MBC
• RT in MBC plays an important role in palliation (i.e., 
uncontrolled pain, spinal cord compression or fractures) 
(LC high; GR A).
Treatment of bone metastases
Bisphosphonates and other osteoclast inhibitors have shown 
to be effective in reducing morbidity of metastatic bone 
disease with respect to skeletal-related events (SREs) and 
should be added to anti-tumor therapy in patients with bone 
metastases [109] (Level of certainly high; GR A).
• The most appropriate duration of anti-resorptive therapy 
(bisphosphonates, denosumab) in BC patients with bone 
metastases is unknown. Two randomized controlled trials 
have demonstrated that, after at least 1 year of standard 
monthly antiresorptive therapy, zoledronic acid every 
12 weeks is non-inferior to every 4 weeks with respect to 
SREs [110, 111], and thus it may represent a new option 
in clinical practice (LC high; GR A).
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